In less than a month, the FDA approved a second medication for hepatitis C virus (HCV) infection. The newer entry into the treatment arena is the first drug capable of suppressing viral load to undetectable levels in only 8 weeks.
In less than a month, the FDA approved a second medication for hepatitis C virus (HCV) infection. The newer entry into the treatment arena is the first drug capable of suppressing viral load to undetectable levels in only 8 weeks.